MoonLake Immunotherapeutics (MLTX) is a clinical-stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases. The company is primarily engaged in the development of Sonelokimab (SLK), a novel tri-specific IL-17A and IL-17F inhibiting Nanobody. MLTX aims to address significant unmet needs in dermatology and rheumatology through its innovative therapeutic approach.
- Sonelokimab (SLK) - Develops a tri-specific IL-17A and IL-17F inhibiting Nanobody for treating inflammatory diseases such as Hidradenitis Suppurativa, Psoriatic Arthritis, and Psoriasis. SLK offers advantages like high affinity, selective binding, and enhanced tissue penetration due to its small size and albumin-binding domain.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Dr. Jorge Santos da Silva Executive | Chief Executive Officer | Professor and Board Advisor at the School of Medicine at Minho University (Portugal). | Co-founder of MoonLake AG; leads MLTX's development of Nanobody® sonelokimab for inflammatory diseases. | View Report → |
Dr. Kristian Reich Executive | Chief Scientific Officer | Guest-Professor at University Medical Center Hamburg-Eppendorf; Medical Advisor at TFS HealthScience; Board Member at Derma2go AG, Dermagnostix GmbH, and ProDerma Foundation. | Co-founder of MoonLake AG; global clinical leader in dermatology and immunology with over 25 years of experience and 300+ peer-reviewed publications. | |
Matthias Bodenstedt Executive | Chief Financial Officer | None | Former McKinsey Partner; oversees MLTX's financial strategy, including maintaining a strong cash position and supporting clinical development programs. | |
Catherine Moukheibir Board | Director | Chair of Audit Committees at Ironwood Pharmaceuticals, Biotalys, Oxford Biomedica, CMR Surgical, Asceneuron, and DNA Script. | Financial expert with extensive board experience in life sciences companies across the U.S. and Europe. | |
Dr. Andrew Phillips Board | Director | CEO and President of Aleksia Therapeutics, Nexo Therapeutics, and Blossom Bioscience; Director at Enliven Therapeutics and multiple private biotechnology companies. | Leader in life sciences-focused investment management and executive roles in biopharmaceutical companies. | |
Dr. Ramnik Xavier Board | Director | Core Institute Member at Broad Institute; Director of Klarman Cell Observatory and Broad's Immunology Program; Co-Director of Broad's Infectious Disease and Microbiome Program; Professor at Harvard Medical School. | Renowned biomedical researcher specializing in genetic variants, computational biology, and immunology; holds multiple leadership roles at prestigious institutions. | |
Simon Sturge Board | Independent Chairperson | Director at Galapagos NV; Director at two private biotechnology companies, a private consulting company, and a private investment company. | Former CEO of Kymab Ltd and COO of Merck Group Germany; extensive experience in biotechnology and pharmaceutical leadership. | |
Spike Loy Board | Director | Managing Director at BVF Partners L.P.; Director at multiple private biopharmaceutical companies. | Experienced in life sciences investment management and biopharmaceutical company leadership. |
Research analysts covering MoonLake Immunotherapeutics.
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
MoonLake Immunotherapeutics AG | 2022 | Deal value and structure: Completed on April 5, 2022, under a Business Combination Agreement dated October 4, 2021, with Helix Acquisition Corp. contributing $134,646,009 (including a $15,000,000 loan repayment), converting Series A preferred to common shares and issuing new classes of shares. Strategic rationale and capabilities: The acquisition advanced the development of Sonelokimab, a novel Nanobody® for treating inflammatory diseases, and repositioned the company with a new Nasdaq listing under MLTX. |
Merck Healthcare KGaA (SLK program) | 2021 | Strategic rationale and capabilities: The SLK program, focused on a tri-specific IL-17A/F nanobody that binds human albumin to extend its half-life, is positioned to be best-in-class for IL-17-driven inflammatory diseases, especially in a $44 billion market, with robust Phase II data in psoriasis supporting its development. Notable aspects: Although detailed deal value and structure were not provided, the acquisition strategically expands MoonLake's asset portfolio to target multiple inflammatory indications and compete against drugs like Bimekizumab. |
Recent press releases and 8-K filings for MLTX.
- MoonLake Immunotherapeutics (MLTX) is facing a securities class action lawsuit following disastrous Phase 3 trial results for its only product candidate, sonelokimab (SLK), a treatment for skin disease.
- On September 29, 2025, MoonLake's share price cratered $55.75, or about 90%, after the announcement of the trial results on September 28, 2025.
- The lawsuit alleges that MoonLake misled investors about SLK’s trial design and efficacy data, particularly regarding its purported advantages over a competitor's FDA-approved product, BIMZELX.
- The Class Period for the lawsuit is March 10, 2024, to September 29, 2025, with a Lead Plaintiff Deadline of December 15, 2025.
- A securities class action has been filed against MoonLake Immunotherapeutics (MLTX) following disastrous Phase 3 trial results for its only product candidate, sonelokimab (SLK), announced on September 28, 2025.
- Following this announcement, MoonLake's share price cratered $55.75, or about 90%, on September 29, 2025.
- The lawsuit alleges that MoonLake misled investors about SLK's trial design and efficacy data, particularly regarding its purported superior clinical benefits compared to a competitor's product, BIMZELX.
- The class period for the lawsuit is from March 10, 2024, to September 29, 2025, with a lead plaintiff deadline of December 15, 2025.
- MoonLake Immunotherapeutics (MLTX) is facing a securities class action lawsuit, Bridgewood v. MoonLake Immunotherapeutics, et al., after the company announced disastrous Phase 3 trial results for its sole product candidate, sonelokimab (SLK), for hidradenitis suppurativa (HS).
- The lawsuit alleges that MoonLake misled investors about SLK’s trial design and efficacy data prior to September 28, 2025.
- Following the announcement, MoonLake investors saw their share price crater $55.75, or about 90%, on September 29, 2025.
- The Class Period for the lawsuit is March 10, 2024 – September 29, 2025, with the Lead Plaintiff Deadline set for December 15, 2025.
- MoonLake Immunotherapeutics ended the third quarter of 2025 with $380.5 million in cash, cash equivalents, and short-term marketable debt securities, which are expected to fund operations into the second half of 2027.
- The company reported positive results from its Phase 2 LEDA clinical trial in Palmoplantar Pustulosis (PPP), with sonelokimab (SLK) demonstrating a 64% mean percent change from baseline in PPPASI at week 16 and 39% of patients achieving PPPASI75.
- Research and development expenses for the quarter ended September 30, 2025, were $60.6 million, while general and administrative expenses were $10.8 million.
- A Type B meeting with the FDA is scheduled for December 15, 2025, to discuss the clinical evidence package for SLK in Hidradenitis Suppurativa (HS) to support a Biologics License Application (BLA), which is anticipated for submission in Q3/Q4 2026.
- Faruqi & Faruqi, LLP is investigating MoonLake Immunotherapeutics (MLTX) for alleged federal securities law violations related to false or misleading statements about its drug SLK's efficacy.
- The investigation follows MoonLake's September 28, 2025, announcement of Phase 3 VELA program results, which showed SLK failed to demonstrate competitive efficacy compared to BIMZELX.
- Following this announcement, MoonLake's stock price plummeted $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025.
- Investors who suffered losses exceeding $10,000 between March 10, 2024, and September 29, 2025, are encouraged to seek the role of lead plaintiff by the December 15, 2025, deadline.
- MoonLake Immunotherapeutics (MLTX) is facing a securities class action lawsuit following the announcement of disastrous Phase 3 trial results for its only product candidate, sonelokimab (SLK).
- On September 29, 2025, MoonLake investors saw the price of their shares crater $55.75, or about 90%, in response to the trial results.
- The lawsuit alleges that MoonLake misled investors about SLK’s trial design and efficacy data, specifically regarding its purported advantages over a competitor's FDA-approved product, BIMZELX.
- The class period for the lawsuit is from March 10, 2024, to September 29, 2025, with a lead plaintiff deadline of December 15, 2025.
- MoonLake Immunotherapeutics (MLTX) is facing a securities class action lawsuit, styled Bridgewood v. MoonLake Immunotherapeutics, et al., following disastrous Phase 3 trial results for its sole product candidate, sonelokimab (SLK), a treatment for skin disease.
- The announcement of the trial results caused MoonLake's share price to crater $55.75, or about 90%, on September 29, 2025.
- The lawsuit alleges that MoonLake misled investors about SLK's trial design and efficacy data, specifically regarding its purported superior clinical benefit over a competitor's product, BIMZELX.
- The class period for the lawsuit is from March 10, 2024, to September 29, 2025, with a lead plaintiff deadline of December 15, 2025.
- MoonLake Immunotherapeutics (MLTX) is facing a securities class action lawsuit, styled Bridgewood v. MoonLake Immunotherapeutics, et al., following disastrous Phase 3 trial results for its only product candidate, sonelokimab (SLK).
- The lawsuit alleges that MoonLake misled investors about SLK's trial design and efficacy data, particularly regarding its purported advantages over a competitor's product, BIMZELX.
- On September 29, 2025, following the announcement of the trial results, MoonLake's share price cratered $55.75, representing approximately a 90% decrease.
- The class period for the lawsuit is from March 10, 2024, to September 29, 2025, with a lead plaintiff deadline of December 15, 2025.
- A class action lawsuit has been filed against MoonLake Immunotherapeutics (MLTX) and certain of its officers by Bronstein, Gewirtz & Grossman, LLC.
- The lawsuit alleges that MoonLake misrepresented the efficacy of its drug candidate, sonelokimab (SLK), by claiming superiority without evidence and omitting material facts about its comparative performance.
- The complaint states that "disastrous" Phase 3 trial results for SLK revealed the drug's shortcomings, causing MoonLake's stock to lose nearly 90% of its value.
- The class period for the lawsuit is between March 10, 2024, and September 29, 2025, inclusive.
- Investors who suffered a loss in MoonLake have until December 15, 2025, to request to be appointed as lead plaintiff.
- A class action lawsuit has been filed against MoonLake Immunotherapeutics (MLTX), alleging false and misleading statements concerning the company's business, operations, and prospects.
- The lawsuit covers investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025.
- Allegations include misleading statements about the purported superiority of its drug candidate, sonelokimab (SLK), over traditional monoclonal antibodies.
- On September 28, 2025, MoonLake announced Phase 3 VELA program results showing SLK failed to demonstrate competitive efficacy, which led to the stock price declining $55.75 per share, or 89.9%, to close at $6.24 on September 29, 2025.
- The deadline for investors to move the Court to serve as lead plaintiff is December 15, 2025.